Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma

Urology

Volumn 49, Issue 5, 1997, Pages 721-725

  Bazinet, Michel ^a   Zheng, Wei ^a   Bégin, Louis R ^a   Aprikian, Armen G ^a,b   Karakiewicz, Pierre I ^a   Elhilali, Mostafa M ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYPROTERONE ACETATE; CYTOKERATIN; EOSIN; FLUTAMIDE; GOSERELIN; HEMATOXYLIN; LEUPRORELIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS;

EID: 0030989096     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00062-9     Document Type: Article

References (19)

1. Bigg SW, Kavoussi LR, and Catalona WJ: Role of nerve sparing radical prostatectomy for clinical stage B2 prostate cancer. J Urol 144: 1420-1424, 1990.
2. Stamey TA, Villers AA, McNeal JE, Link PC, and Freiha FS: Positive surgical margins at radical prostatectomy: importance of the apical dissection. J Urol 143: 1166-1172, 1990.
3. Jones EC: Resection margin status in radical retropubic prostatectomy specimens: relationship to type of operation, tumor size, tumor grade and local tumor extension. J Urol 144: 89-93, 1990.
4. Brendler CB, and Walsh PC: The role of radical prostatectomy in the treatment of prostate cancer. CA Cancer J Clin 42: 212-222, 1992.
5. Rosen MA, Goldstone L, Lapin S, Wheeler T, and Scardino PT: Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 148: 331-337, 1992.
6. Soloway M, Sharifi R, Wood D, Wajsman Z, McLeod D, and Puras A: Randomized comparison of radical prostatectomy alone or preceded by androgen deprivation for cT2b prostate cancer (abstract 650). J Urol 153(suppl): 391A, 1995.
7. Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Tetu B, et al: Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 16: 499-509, 1993.
8. Pedersen KV, Lundberg S, Hugosson J, Aus G, Schelin S, Schain M, Ahlgren G, and Abrahamsson PA, for the Swedish POPCORN Group: Neoadjuvant hormonal treatment with triptorelin versus no treatment prior to radical prostatectomy: a prospective randomized multicenter study (abstract 651). J Urol 153(suppl): 391A, 1995.
9. Goldenberg SL, Klotz LH, Jewett MAS, Srigley J, Barkin J, Mador D, Fradet Y, Chin JL, Paquin JM, and Laplante S, for the Canadian Urological Oncological Group: Randomized, controlled study of neoadjuvant reversible androgen withdrawal therapy with cyproterone acetate in the surgical management of localized prostate cancer (abstract 103).J Urol 153 (suppl): 254A, 1995.
10. Aprikian AG, Fair WR, Reuter VE, Sogani P, Herr H, Russo P, and Sheinfeld J: Experience with neoadjuvant diethylstilbestrol and radical prostatectomy in patients with locally advanced prostate cancer. Br J Urol 74: 630-636, 1994.
11. Murphy WM, Soloway MS, and Barrows GH: Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68: 821-828, 1991.
12. Taylor CR: Immunomicroscopy: A Diagnostic Tool for the Surgical Pathologist, 2nd ed. Philadelphia, WB Saunders, 1994, pp 323-329.
13. Nadji M, and Morales AR: Immunohistochemical techniques, in Silverberg SG (Ed): Principles and Practice of Surgical Pathology. Melbourne, Churchill Livingstone, 1990, vol l, pp 103-118.
14. McNeal JE, Villers AA, Redwine EA, Freihs FS, and Stamey TA: Capsular penetration in prostate cancer. Significance for natural history and treatment. Am J Surg Pathol 14: 240-247, 1990.
15. Bellavance G, and Fradet Y: Influence of neoadjuvant hormonotherapy on PSA response and pathological stage at radical prostatectomy (abstract 1360). J Urol 155(suppl): 651A, 1996.
16. Soloway MS, Sharifi L, Wajsman Z, McLeod D, Wood D Jr, Paras-Baez A, and the Lupron Depot Neoadjuvant Study Group: Randomized prospective study - radical prostatectomy alone vs radical prostatectomy preceded by androgen blockade in cT2b prostate cancer - initial results (abstract 976). J Urol 155(suppl): 555A, 1996.
17. Tetu B, Srigley JR, Boivin JC, Dupont A, Monfette G, Pinault S, and Labrie F: Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am J Surg Pathol 15: 111-120, 1991.
18. Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, Fair WR, and Reuter VE: Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 18: 979-991, 1994.
19. Vailancourt L, Tetu B, Fradet Y, Dupont A, Gomez J, Cusan L, Suburu R, Diamond P, Candas B, and Labrie F: Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study. Am J Surg Pathol 20: 86-93, 1996.